ArticleEClinicalMedicine2022

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.

Dean A Fennell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.